Kazuyuki Suzuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kazuyuki Suzuki has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Hiromasa Morikawa
2 shared publicationsRyoko Narui
2 shared publications- Shion Kachi
Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University , Kyoto
2 shared publications Hiromi Wada
1 shared publication- Hiromi Wada
Japanese Society on Inflammation and Metabolism in Cancer
1 shared publication Reo Hamaguchi
1 shared publication
Latest Publications
- Open Access
- 17 February 2026
- Published by Elsevier in SSRN Electronic Journal
Improved survival in patients with stage IV pancreatic cancer treated with alkalization therapy
This retrospective study evaluated survival outcomes in patients receiving “alkalization therapy” and explored factors associated with long-term survival. We reviewed clinical records of consecutive patients with stage IV pancreatic cancer who visited the Karasuma Wada clinic between January 2011 and December 2019. All patients received alkalization therapy consisting of low–potential renal acid load dietary guidance plus oral citrate and/or bicarbonate; standard oncologic treatment was generally limited to supportive care. Patients with ≥3 outpatient visits and ≥3 urinary pH measurements were included. Overall survival (OS) was estimated using the Kaplan–Meier method and compared between groups stratified by 12.5% trimmed mean urinary pH, defined as the mean after excluding the first and last 12.5% of pH measurements by visit order. Of 125 eligible patients, 102 met the inclusion criteria (median age 66 years [IQR 58–73]); the liver was the most common metastatic site. The 1-, 3-, and 5-year OS rates were 56.2%, 22.7%, and 15.9%, respectively. OS differed significantly between patients with trimmed mean urinary pH ≥6.5 versus <6.5 (log-rank p=0.0024; Wilcoxon p=0.0014). In the pH ≥6.5 group (n=75), OS was 19.8% (95% CI 10.1–35.2) at 5 years and 11.9% (95% CI 5.8–28.5) at 10 years. Survival among non-surgical patients was comparable to that of patients with postoperative recurrence. Long-term survival was observed in a subset, and higher urinary pH was associated with longer survival. Prospective controlled studies are needed to validate clinical benefit and clarify urinary pH as a biomarker.
- 17 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImproved survival in patients with stage IV pancreatic cancer treated with alkalization therapy
This retrospective study evaluated survival outcomes in patients receiving “alkalization therapy” and explored factors associated with long-term survival. We reviewed clinical records of consecutive patients with stage IV pancreatic cancer who visited the Karasuma Wada clinic between January 2011 and December 2019. All patients received alkalization therapy consisting of low–potential renal acid load dietary guidance plus oral citrate and/or bicarbonate; standard oncologic treatment was generally limited to supportive care. Patients with ≥3 outpatient visits and ≥3 urinary pH measurements were included. Overall survival (OS) was estimated using the Kaplan–Meier method and compared between groups stratified by 12.5% trimmed mean urinary pH, defined as the mean after excluding the first and last 12.5% of pH measurements by visit order. Of 125 eligible patients, 102 met the inclusion criteria (median age 66 years [IQR 58–73]); the liver was the most common metastatic site. The 1-, 3-, and 5-year OS rates were 56.2%, 22.7%, and 15.9%, respectively. OS differed significantly between patients with trimmed mean urinary pH ≥6.5 versus <6.5 (log-rank p=0.0024; Wilcoxon p=0.0014). In the pH ≥6.5 group (n=75), OS was 19.8% (95% CI 10.1–35.2) at 5 years and 11.9% (95% CI 5.8–28.5) at 10 years. Survival among non-surgical patients was comparable to that of patients with postoperative recurrence. Long-term survival was observed in a subset, and higher urinary pH was associated with longer survival. Prospective controlled studies are needed to validate clinical benefit and clarify urinary pH as a biomarker.
- Open Access
- 21 January 2026
- Published by Elsevier in Translational Oncology
- Vol. 65, 102677
Five-year survival of patients with non-small cell lung cancer treated with alkalization therapy
- 21 January 2026
- Published by Elsevier in Translational Oncology
- Vol. 65, 102677
Open AccessFive-year survival of patients with non-small cell lung cancer treated with alkalization therapy
- Open Access
- 25 October 2023
- Published by Qeios Ltd
Review of: "Real-World Efficacy of N95, Surgical, and Cloth Masks in Mitigating SARS-CoV-2 Respiratory Infections: A Comprehensive Comparative Study"
1. At the final paragraph, the authors mentioned the following: “Lastly, given the evolving nature of respiratory viruses and the emergence of new variants, ongoing research is necessary to evaluate the effectiveness of masks against emerging strain...
- 25 October 2023
- Published by Qeios Ltd
Open AccessReview of: "Real-World Efficacy of N95, Surgical, and Cloth Masks in Mitigating SARS-CoV-2 Respiratory Infections: A Comprehensive Comparative Study"
1. At the final paragraph, the authors mentioned the following: “Lastly, given the evolving nature of respiratory viruses and the emergence of new variants, ongoing research is necessary to evaluate the effectiveness of masks against emerging strain...